Rhein Biotech acquires Hep-B company

Rhein Biotech (NMarkt:RBO) acquired 80 percent of Green Cross Vaccine (Seoul, Korea), a division of Korea Green Cross and a partner of RBO's since 1993, for $110 million, consisting of cash and 700,00...